Q1 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$209M+125.8% YoY

Gross Profit

$129M61.8% margin

Operating Income

$59M28.2% margin

Net Income

$43M20.6% margin

EPS (Diluted)

$0.61

QoQ Revenue Growth

+61.2%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

$7M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$933M

Total Liabilities

$417M

Stockholders' Equity

$516M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$209M	$93M	+125.8%
Gross Profit	$129M	$41M	+214.6%
Operating Income	$59M	$16M	+277.2%
Net Income	$43M	$9M	+376.9%

Revenue Segments

Product

$180M30%

Radiopharmaceutical Oncology

$94M16%

PYLARIFY

$93M16%

Total Precision Diagnostics

$86M14%

DEFINITY

$58M10%

License and Royalty Revenues

$29M5%

Strategic Partnerships And Other

$29M5%

Techne Lite

$23M4%

Other Precision Diagnostics

$5M1%

Other Radiopharmaceutical Oncology

$1M0%